Bank Of New York Mellon Corp C4 Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$3.1 - $9.02 $469,826 - $1.37 Million	151,557 New	151,557 $476 Million
Q4 2022 Feb 14, 2023	BUY	$5.42 - $10.24 $826,560 - $1.56 Million	152,502 New	152,502 $899,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $147,205 - $234,099	18,332 Added 13.73%	151,836 $1.33 Million
Q2 2022 Aug 15, 2022	BUY	$5.06 - $26.46 $32,545 - $170,190	6,432 Added 5.06%	133,504 $1.01 Million
Q1 2022 May 11, 2022	BUY	$19.99 - $33.23 $32,003 - $53,201	1,601 Added 1.28%	127,072 $3.08 Million
Q4 2021 Feb 11, 2022	BUY	$29.39 - $46.86 $378,337 - $603,228	12,873 Added 11.43%	125,471 $4.04 Million
Q3 2021 Nov 12, 2021	BUY	$35.91 - $50.5 $1.01 Million - $1.42 Million	28,053 Added 33.18%	112,598 $5.03 Million
Q2 2021 Aug 11, 2021	BUY	$30.39 - $42.18 $1.67 Million - $2.32 Million	55,028 Added 186.43%	84,545 $3.2 Million
Q1 2021 May 13, 2021	BUY	$31.96 - $46.5 $37,584 - $54,684	1,176 Added 4.15%	29,517 $1.09 Million
Q4 2020 Feb 09, 2021	BUY	$22.8 - $37.05 $646,174 - $1.05 Million	28,341 New	28,341 $938,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $178M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.